Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Daclizumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    24 result(s) found for: Daclizumab. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2016-002820-10 Sponsor Protocol Number: 205MS305 Start Date*: 2017-03-13
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) Switching from Nataliz...
    Medical condition: Remitting-Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001567-55 Sponsor Protocol Number: DAC-1012 Start Date*: 2006-06-23
    Sponsor Name:Protein Design Labs, Inc.
    Full Title: A Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients with Active, Relapsing Forms of Multiple Sclerosis
    Medical condition: This study is performed in patients with relapsing forms of Multiple Sclerosis. Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS), thought ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003383-39 Sponsor Protocol Number: ML18690 Start Date*: 2005-12-29
    Sponsor Name:Roche Farma S.A.
    Full Title: A randomized, open-label, multi-center study comparing a steroid sparing regimen versus standard steroid regimen in combination with daclizumab, mycophenolate mofetil and sirolimus in the preventio...
    Medical condition: Renal Transplant
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-015318-23 Sponsor Protocol Number: 205MS203 Start Date*: 2010-01-21
    Sponsor Name:Biogen Idec Ltd.
    Full Title: A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Efficacy of Daclizumab High Yield Process (DAC HYP) Monotherapy in Subjects with Multiple Sclerosis Who Have Complete...
    Medical condition: Relapsing-remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-003176-39 Sponsor Protocol Number: 205MS303 Start Date*: 2013-05-31
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Hav...
    Medical condition: Relapsing-remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended) CZ (Completed) HU (Completed) PL (Completed) SE (Completed) ES (Completed) IE (Prematurely Ended) GB (Completed) FI (Prematurely Ended) GR (Completed) FR (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-005559-46 Sponsor Protocol Number: 205MS202 Start Date*: 2009-01-23
    Sponsor Name:Biogen Idec Ltd.
    Full Title: A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT)
    Medical condition: Relapsing-remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-012500-11 Sponsor Protocol Number: 205MS301 Start Date*: 2010-04-12
    Sponsor Name:Biogen Idec Ltd
    Full Title: Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β...
    Medical condition: Relapsing-remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) FR (Completed) DE (Completed) CZ (Completed) HU (Completed) FI (Completed) SE (Completed) ES (Completed) GB (Completed) GR (Completed) IT (Completed) DK (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2010-023856-97 Sponsor Protocol Number: 205MS302 Start Date*: 2011-09-22
    Sponsor Name:Biogen Idec Limited
    Full Title: A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Immunogenicity and Pharmacokinetics of BIIB019, Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneo...
    Medical condition: Relapsing-remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-003023-20 Sponsor Protocol Number: UCL-PLTP-002 Start Date*: 2008-09-11
    Sponsor Name:Cliniques universitaires Saint-Luc
    Full Title: TACROLIMUS – DACLIZUMAB - MYCOPHENOLATE MOFETIL IMMUNE PROPHYLAXIS IN PEDIATRIC LIVER TRANSPLANTATION. An open, pilot, investigator-driven study in 20 recipients
    Medical condition: Liver transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024678 Liver failure LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001496-35 Sponsor Protocol Number: ISRCTN07963178 Start Date*: 2006-02-13
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: A single centre, randomised controlled, open label study of rituximab as induction therapy in kidney transplantation.
    Medical condition: Renal Transplantation
    Disease: Version SOC Term Classification Code Term Level
    7.1 10038533 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001161-42 Sponsor Protocol Number: 205-MS-201 Start Date*: 2006-08-29
    Sponsor Name:Biogen Idec Ltd
    Full Title: Multicentre, double-blind, placebo-controlled, dose-ranging study to determine the safety and efficacy of daclizumab HYP (DAC HYP) as a monotherapy treatment in subjects with relapsing-remitting mu...
    Medical condition: Multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) SE (Prematurely Ended) DE (Prematurely Ended) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-001854-25 Sponsor Protocol Number: SATOT42005 Start Date*: 2005-12-05
    Sponsor Name:Sociedad Andaluza de Trasplante de Órganos y Tejidos
    Full Title: Estudio comparativo de tacrolimus y rapamicina para evaluar la función renal en pacientes mayores de 50 años, receptores de un riñón de donante mayor de 55 años, en un régimen inmunosupresor de dac...
    Medical condition: Trasplante renal en pacientes mayores de 50 años, receptores de un riñón de donante mayor de 55 años.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002924-16 Sponsor Protocol Number: FG-506-01-IT-02 Start Date*: 2004-10-22
    Sponsor Name:FUJISAWA
    Full Title: AN OPEN, MULTICENTRE, RANDOMISED PARALLEL GROUP CLINICAL STUDY TO COMPARE SAFETY AND EFFICACY OF TACROLIMUS FK506 WITH MONOCLONAL ANTI-IL2R ANTIBODIES DACLIZUMAB VS TACROLIMUS FK506 WITH STER...
    Medical condition: PREVENTION OF REJECTION OF SUBOPTIMAL LIVERS IN LIVER ALLOGRAFT RECIPIENTS. COMPARE SAFETY AND EFFICACY OF TACROLIMUS FK506 WITH MONOCLONAL ANTI-IL2R ANTIBODIES DACLIZUMAB VS TACROLIMUS FK506 ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019654 Hepatic and hepatobiliary disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004561-14 Sponsor Protocol Number: FG-506-01-28 Start Date*: 2005-04-12
    Sponsor Name:Astellas Pharma Europe Ltd
    Full Title: AN OPEN, RANDOMISED, MULTICENTRE, EXPLORATORY CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TACROLIMUS IN COMBINATION WITH MONOCLONAL ANTI-IL2R ANTIBODIES OR STEROIDS IN HCV POSITIVE PATIENT...
    Medical condition: Patients 18 to 65 years of age who will undergo primary orthotopic liver or split liver allograft transplantation for HCV-cirrhosis. As the primary endpoint of the study is the viral load of HCV th...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10057394 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) SE (Completed) GB (Completed) ES (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000904-15 Sponsor Protocol Number: 808040002 Start Date*: 2008-11-03
    Sponsor Name:George Washington University Biostatistics Center
    Full Title: Intervention with mycophenolate mofetil and daclizumab in patients with recently diagnosed type 1 diabetes mellitus
    Medical condition: Type 1 diabetes, recently diagnosed
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-005055-33 Sponsor Protocol Number: ML17443 Start Date*: 2005-09-01
    Sponsor Name:Barts and the London NHS Trust
    Full Title: Evaluating the safety and efficacy of mycophenolate mofetil, daclizumab and a single, initial week of corticosteroids in combination with tacrolimus or sirolimus with continued steroid as mainstay ...
    Medical condition: Renal Transplantation
    Disease: Version SOC Term Classification Code Term Level
    7.1 10038533 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006652-35 Sponsor Protocol Number: ML 20958 Start Date*: 2007-09-28
    Sponsor Name:Queen Mary University of London
    Full Title: A pilot study to evaluate of the impact on bone density during treatment with mycophenolate mofetil, daclizumab in combination with ciclosporin converted to sirolimus with steroid as mainstay immun...
    Medical condition: Renal Transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038533 Renal transplant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001617-34 Sponsor Protocol Number: FG-506-01-27 Start Date*: 2005-03-07
    Sponsor Name:Astellas Pharma GmbH
    Full Title: AN OPEN, RANDOMISED, MULTICENTRE, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TACROLIMUS AND MINIMAL STEROIDS IN COMBINATION WITH EITHER A MONOCLONAL ANTI-IL2R ANTIBODY (DACLIZUMAB) OR MYC...
    Medical condition: Patients with hepatic disease who will undergo primary orthotopic liver or split liver allograft transplantation.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10019650 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SE (Completed) FI (Completed) DK (Completed) ES (Completed) IT (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-004115-38 Sponsor Protocol Number: IOP (noncommercial trial) Start Date*: 2005-03-22
    Sponsor Name:University Hospital Antwerp
    Full Title: Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A prospective, randomised trial of Sirolimus versus Cyclosporine.
    Medical condition: patients with end-stage renal failure treated with renal transplantation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000363-10 Sponsor Protocol Number: 0468H1-101497 Start Date*: 2004-11-08
    Sponsor Name:Wyeth Pharmaceuticals
    Full Title: A Randomized Open Label Study to compare the Safety and Efficacy of Two Different Sirolimus Regimens with a Tacrolimus + Mycophenolate Mofetil Regimen in de novo Renal Allograft Recipients
    Medical condition: de novo Renal Allograft Recipients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 08:37:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA